Response to: Correspondence on 'ACR/EULAR antiphospholipid syndrome classification criteria by Damoiseaux and van Beers

We appreciate the comments by Damoiseaux and van Beers1 in response to the publication of the 2023 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) Antiphospholipid Syndrome (APS) classification criteria.2 3 Here, we address a few of the authors points, including: (1) choosing ELISA for antiphospholipid antibodies (aPL) as compared with automated methods, is ‘disputable’; (2) anticardiolipin antibody (aCL) and anti-β2-glycoprotein-I antibody (aβ2GPI) IgM alone, or single one-time lupus-anticoagulant (LA) positivity alone is ‘not of any value for classification’; (3) although ‘high’ aCL/aβ2GPI level receives more points, ‘this has no effect on the dichotomous outcome of the classification criteria’; and (4) differentially scoring aCL/aβ2GPI levels ‘is not really effectuated’. Regarding the first point, we refer the authors to our response4 to the correspondence by Miro-Mur et al5 on the 2023 ACR/EULAR APS classification criteria. Additionally, we want...
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Tags: ARD Correspondence response Source Type: research